{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 46 of 122', 'Adverse event: Any unfavorable and unintended sign (including an abnormal laboratory', 'finding), symptom, or disease temporally associated with the study treatment, whether or not', 'related to the study treatment.', 'Examples of adverse events include the following:', 'A new event or experience that was not present at screening/baseline', 'A worsening, excluding minor fluctuations, in the nature, severity, frequency, or', 'duration of a pre-existing condition', 'An investigational abnormality (eg, PEFR/FEV1 measurements, laboratory tests, vital', 'signs) only if the abnormality is considered clinically significant by the', 'investigator (eg, associated with clinically significant symptoms, requires additional', 'diagnostic testing or intervention, leads to change in study product dosing or', 'discontinuation from the study)', 'An adverse event does not include the following:', 'Pre-existing diseases or conditions present or detected before the start of study', 'treatment that do not worsen', 'SPT reactions, unless the reaction or a complication from the procedure is considered', 'a serious adverse event', 'Situations where an untoward medical event has not occurred (eg, planned', 'hospitalization for an elective procedure)', 'Adverse reaction: Any adverse event considered to be caused by the study product.', 'Serious adverse events: Any adverse event that meets any of the criteria in Table 8 as', 'determined by the investigator or sponsor.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 47 of 122', 'Table 8: Criteria for Serious Adverse Events', 'Subject Outcome', 'Comments', 'Death', 'Death is an outcome, not an adverse event. The primary adverse', 'event resulting in death should be identified.', 'Life-threatening', 'At immediate risk of death from the adverse event (eg, from the', 'combination of severe anaphylaxis and a grade 4 allergic reaction', 'per Section 8.4).', 'Inpatient hospitalization or', 'Does not include prolonged hospitalization for extended', 'prolongation of existing hospitalization', 'observation (eg, to watch for a delayed or biphasic reaction) or', 'planned hospitalization (eg, for an elective procedure).', 'Disability or permanent damage', 'Persistent or significant incapacity or substantial disruption of the', 'ability to conduct normal life functions.', 'Congenital abnormality or birth defect', 'Important medical event', 'An event that may jeopardize the health of the subject or require', 'medical or surgical intervention to prevent any of the other', 'outcomes.', 'In general, anaphylaxis classified as an important medical event', 'should require an emergency department visit with intensive', 'therapy (determined by the investigator, but may include', 'interventions such as intravenous epinephrine, intubation, or', 'admission to an intensive care unit; 1-2 intramuscular injections of', 'epinephrine are typically not considered intensive therapy).', 'If anaphylaxis of mild or moderate severity and without', 'administration of intensive therapy is reported as an important', 'medical event, a clinical assessment by the investigator and reason', 'for the assessment must be included in the event narrative.', 'Source: ICH E2A and US Code of Federal Regulations: 21 CFR 312.32 [75 FR 59961].', 'Unexpected adverse events: Adverse events for which the nature or severity is not consistent', 'with the reference safety information.', 'Suspected unexpected serious adverse reactions (SUSARs): Adverse events assessed as', 'serious, related to study product, and unexpected, which are subject to expedited reporting to', 'regulatory authorities and study investigators.', 'Adverse events of interest: Adverse events of interest are any adverse events (serious or', 'nonserious) identified for ongoing monitoring during the study and require rapid', 'communication by the investigator to the sponsor as described in Section 8.5.6.', '8.3', 'Assessment of Causal Relationship', 'The investigator will assess the relationship of an adverse event to study product as related or', 'not related (ie, if there is a reasonable possibility that the study product caused the event),', \"and document the relationship in the subject's source documents.\"]['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 48 of 122', '8.4 Assessment of Severity (Intensity)', 'Severity describes the intensity of a specific adverse event (eg, mild, moderate, severe,', 'life-threatening, or death). The particular event may be of relatively minor medical', 'significance (such as severe headache). Severity is not the same as \"serious,\" which is based', 'on subject/event outcome or action criteria.', 'Investigators will grade the severity of adverse events. The severity of an adverse event is to', \"be recorded on the case report form and in the subject's source documents.\", 'Three different severity grading systems will be used depending on type of adverse event:', 'allergic reactions, anaphylaxis, or all other adverse events. Brief descriptions of the', '3 severity grading systems are provided.', 'Severity of allergic reactions will be graded using the Consortium of Food Allergy Research', '(CoFAR grading system (adapted from Burks, 2012), with scores ranging from 1 (transient', 'or mild discomfort) to 5 (death) (Table 9).', 'Table 9: CoFAR Severity Grading System for Allergic Reactions', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Grade 5', 'Mild', 'Moderate', 'Severe', 'Life-Threatening', 'Death', 'Transient or mild', 'Symptoms that', 'Marked limitation in', 'Extreme limitation', 'Death', 'discomforts', 'produce mild to', 'activity, some', 'in activity,', '(< 48 hours), no or', 'moderate limitation', 'assistance usually', 'significant', 'minimal medical', 'in activity, some', 'required; medical', 'assistance required;', 'intervention/therapy', 'assistance may be', 'intervention/therapy', 'significant', 'required.', 'needed; no or', 'required,', 'medical/therapy.', 'minimal', 'hospitalization is', 'Intervention is', 'intervention/therapy', 'possible. Parenteral', 'required;', 'is required.', 'medication(s) are', 'hospitalization is', 'Hospitalization is', 'usually indicated.', 'probable.', 'possible.', 'Symptoms may', 'Symptoms may', 'Symptoms may', 'Symptoms may', 'include pruritus,', 'include persistent', 'include', 'include persistent', 'swelling or rash,', 'hives, wheezing', 'bronchospasm with', 'hypotension and/or', 'abdominal', 'without dyspnea,', 'dyspnea, severe', 'hypoxia with', 'discomfort, or other', 'abdominal', 'abdominal pain,', 'resultant decreased', 'transient symptoms.', 'discomfort/', 'throat tightness with', 'level of', 'increased vomiting,', 'hoarseness, transient', 'consciousness', 'or other symptoms.', 'hypotension, or', 'associated with', 'other symptoms.', 'collapse and/or', 'incontinence, or', 'other', 'life-threatening', 'symptoms.', 'Source: Adapted from Burks, 2012.', 'CoFAR, Consortium of Food Allergy Research.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 49 of 122', 'Severity of anaphylaxis will be graded according to the European Academy of Allergy and', 'Clinical Immunology (EAACI) guidelines (Table 10; adapted from Muraro, 2007). The', 'clinical assessment of anaphylaxis is described in Section 8.5.1.1.', 'Table 10: EAACI Severity Grading System for Anaphylaxis', 'Grade 1', 'Grade 2', 'Grade 3', 'Mild', 'Moderate', 'Severe', 'Skin and subcutaneous tissues', 'Features suggesting respiratory,', 'Hypoxia, hypotension, or', 'only', 'cardiovascular, or', 'neurologic compromise', 'gastrointestinal involvement', 'Generalized erythema, urticaria,', 'Dyspnea, stridor, wheeze,', 'Cyanosis or SpO292% at any', 'periorbital edema or angioedema', 'nausea, vomiting, dizziness', 'stage, hypotension (systolic', '(presyncope), diaphoresis, chest', 'blood pressure < 90 mm Hg in', 'or throat tightness, or abdominal', 'adults), confusion, collapse, loss', 'pain', 'of consciousness, or', 'incontinence', 'Source: Adapted from Muraro, 2007.', 'EAACI; European Academy of Allergy and Clinical Immunology.', 'Severity of all other adverse events will be graded according to the National Cancer Institute', '(NCI) Common Terminology Criteria for Adverse Events (CTCAE). CTCAE terms are', 'grouped by system organ class, graded 1 to 5, and have unique clinical descriptions of', 'severity for each adverse event based on the general guideline presented in Table 11.', 'Table 11: NCI CTCAE Severity Grading System for Adverse Events', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Grade 5', 'Mild', 'Moderate', 'Severe', 'Life-Threatening', 'Death', 'Asymptomatic or', 'Minimal, local, or', 'Severe or medically', 'Life-threatening', 'Death', 'mild symptoms;', 'noninvasive', 'significant but not', 'consequences;', 'related to', 'clinical or diagnostic', 'intervention', 'immediately', 'urgent intervention', 'adverse', 'observations only;', 'indicated; limiting', 'life-threatening;', 'indicated', 'event', 'intervention not', 'age-appropriate', 'hospitalization or', 'indicated', 'instrumental', 'prolongation of', 'activities of daily', 'hospitalization', 'living', 'indicated; disabling;', 'limiting self-care', 'activities of daily', 'living', 'Source: NCI CTCAE.', 'NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events.']", "completion": ""}